Daiichi Sankyo (OTCMKTS:DSNKY) Stock Price Down 6.3% – What’s Next?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) traded down 6.3% during trading on Monday . The stock traded as low as $16.07 and last traded at $16.09. Approximately 1,724 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 370,734 shares. The stock had previously closed at $17.18.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DSNKY. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Daiichi Sankyo Price Performance

The company’s fifty day simple moving average is $16.70 and its two-hundred day simple moving average is $17.43. The stock has a market capitalization of $31.18 billion, a PE ratio of 19.47, a P/E/G ratio of 3.31 and a beta of -0.18. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.64 and a current ratio of 2.42.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, sell-side analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.